Literature DB >> 14730513

Osteoporosis and chronic kidney disease.

Catherine Stehman-Breen1.   

Abstract

Bone disease is heterogenous and highly prevalent among those with chronic kidney disease, stage V (CKD-V) patients. Although we know much regarding the risk factors and outcomes associated with renal osteodystrophy, less is known about osteoporosis in CKD-V. Factors that predict bone loss in the CKD-V population are similar to those in the general population and include female gender, Caucasian race, older age, chronic disease, and immobility. In addition, some studies suggest that chronic acidosis and renal osteodystrophy may also increase the risk for bone loss. Little is known about associated adverse outcomes or the impact of therapeutic interventions for osteoporosis. Although we know that the risk for hip fracture is high among CKD-V patients and that fracture is associated with an increased risk for death, the role that bone loss plays is largely unknown. Current recommendations suggest that risk-factor modification is the most appropriate course of treatment for CKD-V-associated osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14730513     DOI: 10.1053/j.semnephrol.2003.08.013

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  11 in total

1.  Declining Rates of Hip Fracture in End-Stage Renal Disease: Analysis From the 2003-2011 Nationwide Inpatient Sample.

Authors:  Sun Moon Kim; Sai Liu; Jin Long; Maria E Montez-Rath; Mary B Leonard; Glenn M Chertow
Journal:  J Bone Miner Res       Date:  2017-09-11       Impact factor: 6.741

2.  Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease.

Authors:  S Geng; Z Kuang; P L Peissig; D Page; L Maursetter; K E Hansen
Journal:  Osteoporos Int       Date:  2019-05-31       Impact factor: 4.507

3.  Osteoporosis and cardiovascular disease: lessons from chronic kidney disease.

Authors:  Keith A Hruska; Suresh Mathew; Richard Lund
Journal:  Clin Cases Miner Bone Metab       Date:  2008-01

4.  Inflammatory and bone turnover markers in relation to PTH and vitamin D status among Saudi postmenopausal women with and without osteoporosis.

Authors:  Nasser M Al-Daghri; Sobhy Yakout; Eman Al-Shehri; Hanan Al-Fawaz; Naji Aljohani; Yousef Al-Saleh
Journal:  Int J Clin Exp Med       Date:  2014-09-15

5.  Inflammatory and bone turnover markers in relation to PTH and vitamin D status among saudi postmenopausal women with and without osteoporosis.

Authors:  Nasser M Al-Daghri; Sobhy Yakout; Eman Al-Shehri; Hanan A Al-Fawaz; Naji Aljohani; Yousef Al-Saleh
Journal:  Int J Clin Exp Med       Date:  2014-10-15

6.  Bone mineral density and fracture risk in older individuals with CKD.

Authors:  Robert H Yenchek; Joachim H Ix; Michael G Shlipak; Douglas C Bauer; Nahid J Rianon; Stephen B Kritchevsky; Tamara B Harris; Anne B Newman; Jane A Cauley; Linda F Fried
Journal:  Clin J Am Soc Nephrol       Date:  2012-04-19       Impact factor: 8.237

7.  Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation.

Authors:  Jesper Hjortnaes; Jonathan Butcher; Jose-Luiz Figueiredo; Mark Riccio; Rainer H Kohler; Kenneth M Kozloff; Ralph Weissleder; Elena Aikawa
Journal:  Eur Heart J       Date:  2010-07-02       Impact factor: 29.983

8.  High phosphate feeding promotes mineral and bone abnormalities in mice with chronic kidney disease.

Authors:  Wei Ling Lau; Michael Linnes; Emily Y Chu; Brian L Foster; Bryan A Bartley; Martha J Somerman; Cecilia M Giachelli
Journal:  Nephrol Dial Transplant       Date:  2012-10-08       Impact factor: 5.992

Review 9.  Hyperphosphatemia of chronic kidney disease.

Authors:  Keith A Hruska; Suresh Mathew; Richard Lund; Ping Qiu; Raymond Pratt
Journal:  Kidney Int       Date:  2008-04-30       Impact factor: 10.612

Review 10.  Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD).

Authors:  Keith A Hruska; Eric T Choi; Imran Memon; T Keefe Davis; Suresh Mathew
Journal:  Pediatr Nephrol       Date:  2009-11-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.